GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biostax BTAX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

—

FY2014FY2023

Net income

−$2.4m

FY2014FY2023

Free cash flow

−$408,026

FY2014FY2023

Shareholders' equity

−$4.5m

FY2014FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue—————$113,500—$3,500$16,200—
Gross profit—————$65,800————
Research and development$473,528$14,236$152,667$126,259$336,110$144,100$399,400$444,200$977,200$7.5m
Operating income−$1.5m−$1.2m−$738,169−$887,030−$2.8m−$4.1m−$5.9m−$14.3m−$10.6m−$35.4m
Net income−$2.4m−$3.5m$3.6m$1.6m−$3.4m−$8.2m−$7.3m−$19.5m−$14.2m−$48.3m
Diluted earnings per share-0.03-0.040.040.02-0.04-19.03-22.81-90.09-0.09-0.49

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$35,285$963,719$3.1m$10,171$5,816$91,600$195,600$76,400$41,200$6.1m
Cash and short-term investments$29,785$150,491$3.1m$9,971—$5,900$14,700$74,400$23,200$192,000
Total liabilities$4.6m$3.5m$11.1m$11.7m$13.7m$11.3m$6.7m$5.2m$3.9m$4.3m
Debt$1.1m$696,478$3.1m$2.8m—$5.2m$4.8m$4.2m$2.8m$513,500
Shareholders' equity−$4.5m−$2.5m−$7.9m−$11.7m−$13.7m−$11.3m−$6.5m−$5.1m−$3.9m$1.7m
Shares outstanding84m83m84m84m84m0m0m0m153m99m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$408,026−$581,821−$231,717−$191,955−$934−$1.4m−$2.1m−$2.8m−$2.8m−$3.8m
Capital spending—−$500,000———−$2,000−$1,500−$1,700—−$58,500
Free cash flow−$408,026−$1.1m−$231,717−$191,955−$934−$1.4m−$2.1m−$2.8m−$2.8m−$3.9m

Latest quarters

By quarter end

Mar 2025Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023
Operating income−$112,341−$112,340−$300,041−$265,326−$293,225−$352,323−$437,472−$401,818
Net income−$36,197−$36,197−$427,960−$352,635−$341,447−$388,760−$504,234−$416,117
Diluted earnings per share-0.00-0.00-0.01-0.00-0.00-0.00-0.01-0.00
Total assets$5,500$5,500$5,451$7,598$35,285$732,000$758,672$796,728
Cash and short-term investments——−$49$2,098————
Debt$1.2m—$1.2m$1.2m————
Shareholders' equity−$5.3m−$5.3m−$5.3m−$4.9m−$4.5m−$3.5m−$3.1m−$2.8m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income18.7%-18.3%-34.1%
Net income—-22.0%-31.6%

Valuation history

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Price to earnings-1.3-0.91.711.4-2.4—-0.0-0.0-35.4-3.0
Price to sales—————0.3—46.3——

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-99%-74%-48%-41%-43%82%9%-48%-73%-75%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1000-to-1 reverse split · 6 May 2021
  • 1000-to-1 reverse split · 27 Feb 2012
  • 2-for-1 split · 12 Aug 2005
  • 200-to-1 reverse split · 24 Feb 2005
  • 500-to-1 reverse split · 12 Nov 2004

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.